These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 25344864)

  • 1. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway.
    Ardiani A; Gameiro SR; Kwilas AR; Donahue RN; Hodge JW
    Oncotarget; 2014 Oct; 5(19):9335-48. PubMed ID: 25344864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
    Liu C; Armstrong C; Zhu Y; Lou W; Gao AC
    Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
    Pal SK; Moreira D; Won H; White SW; Duttagupta P; Lucia M; Jones J; Hsu J; Kortylewski M
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
    Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
    Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
    Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
    Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
    Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Pilling AB; Hwang C
    Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
    Crespo M; van Dalum G; Ferraldeschi R; Zafeiriou Z; Sideris S; Lorente D; Bianchini D; Rodrigues DN; Riisnaes R; Miranda S; Figueiredo I; Flohr P; Nowakowska K; de Bono JS; Terstappen LW; Attard G
    Br J Cancer; 2015 Mar; 112(7):1166-74. PubMed ID: 25719830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
    Hashimoto K; Tabata H; Shindo T; Tanaka T; Hashimoto J; Inoue R; Muranaka T; Hotta H; Yanase M; Kunishima Y; Takahashi A; Masumori N;
    Urol Oncol; 2019 Jul; 37(7):485-491. PubMed ID: 31103335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
    Ardiani A; Farsaci B; Rogers CJ; Protter A; Guo Z; King TH; Apelian D; Hodge JW
    Clin Cancer Res; 2013 Nov; 19(22):6205-18. PubMed ID: 24048332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.